Pharma and biotech teams developing siRNA therapeutics burn months screening candidates that rarely make it to IND-enabling studies. Few candidates clear potency, safety, and cross-species coverage at once, and the one sequence that finally works is often already claimed in someone else's patent, which sends the whole program back to the start.
Wuya Discovery helps RNAi teams design, screen, and optimize siRNA candidates through OligoThinkā¢, an AI agent wired directly into a high-throughput wet lab. Novelty comes first, not last: OligoThink maps published siRNA claims before it designs, so every candidate starts in open space and is optimized for potency, safety, and cross-species coverage from there.
Traditional workflows drop screening data from each round, so it never feeds back into design. Our AI agent enables every experimental result to sharpen the next round: fewer candidates, stronger hits. Our platform is experimentally validated across more than ten targets, from standalone siRNA to AOC programs.
We deliver end-to-end, from design to wet-lab validation. The datasets, candidates, and IP are all yours: a validated pipeline ready to advance or out-license.